GIMBE - News Cliniche - Pagina 25

Home

News Cliniche - Pagina 25

ONLINE IL SITO GIMBE SULL'EMERGENZA COVID-19

News Cliniche

GIMBE: Eventi, progetti, pubblicazioni e altre attività istituzionali della Fondazione GIMBE
Metodologiche: articoli pertinenti le aree del know-how GIMBE, pubblicati nei top-six journals*
Cliniche: articoli di ricerca clinica primaria e secondaria pubblicati nei top-six journals*
Sanità: notizie dalla sanità italiana
Eventi: congressi, conferenze, workshop nazionali e internazionali relativi alle aree del know-how GIMBE

*N Engl J Med, Lancet, Ann Intern Med, JAMA, BMJ, PLos Med

28 giugno 2018

Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma

N Engl J Med 2018;378:2475-2485

Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma

N Engl J Med 2018;378:2486-2496

26 giugno 2018

Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer. The FRESCO Randomized Clinical Trial

JAMA 2018;319:2486-2496.

Annual Risk of Major Bleeding Among Persons Without Cardiovascular Disease Not Receiving Antiplatelet Therapy

JAMA 2018;319:2507-2520.

Screening to Prevent Osteoporotic FracturesUpdated Evidence Report and Systematic Review for the US Preventive Services Task Force

JAMA 2018;319:2532-2551.

23 giugno 2018

Vitamin D and risk of pregnancy related hypertensive disorders: mendelian randomisation study

BMJ 2018;361:k2167

Self management of patients with mild COPD in primary care: randomised controlled trial

BMJ 2018;361:k2241

Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial

Lancet 2018;391:2503–2512

Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial

Lancet 2018;391:2513-2524

Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial

Lancet 2018;391:2513-2524

23

24

25

26

27

Pagina aggiornata il 30/04/2025